Patents by Inventor Yoshinori Naoe
Yoshinori Naoe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240082300Abstract: Provided is a chimeric target factor receptor capable of activating an antigen-presenting cell such as a dendritic cell in a target-factor-specific manner. The chimeric target factor receptor contains a target factor-binding domain, a transmembrane domain, and an intracellular domain containing a TLR intracellular domain.Type: ApplicationFiled: November 30, 2021Publication date: March 14, 2024Applicant: NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEMInventors: Hideki KASUYA, Yoshinori NAOE, Shigeru MATSUMURA, Ibrahim Ragab Nassr EISSA, Mohamed Abdelmoneim Ahmed ALI MOHAMED
-
Publication number: 20220273739Abstract: Provided are a combination drug for treating a malignant tumor, a pharmaceutical composition for treating a malignant tumor, and a pharmaceutical composition for malignant tumor treatment that have an exceptional antitumor effect. A malignant tumor can be treated by a combination drug containing a first medicine that includes an oncolytic virus belonging to the herpes simplex viruses type 1 as an active ingredient, and a second medicine that includes an interferon gene stimulating factor agonist as an active ingredient.Type: ApplicationFiled: July 30, 2020Publication date: September 1, 2022Inventors: Hideki KASUYA, Yoshinori NAOE, Shigeru MATSUMURA, Ibrahim Ragab Nassr EISSA
-
Patent number: 8822422Abstract: An antitumor agent containing, in combination, at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent, and a histone deacetylase inhibitor. According to the present invention, an antitumor agent causing reduced side effects and having a superior antitumor activity can be provided.Type: GrantFiled: March 11, 2011Date of Patent: September 2, 2014Assignee: Astellas Pharma Inc.Inventors: Yoshinori Naoe, Takeshi Inoue, Yasuhiko Kano
-
Patent number: 8673888Abstract: The present invention provides a therapeutic agent of kidney cancer, which comprises FK228 of the formula (I) or a salt thereof. FK228 or a salt thereof, which is an active ingredient in the present invention, shows a superior antitumor activity in vivo against kidney cancer.Type: GrantFiled: March 27, 2003Date of Patent: March 18, 2014Assignees: The United States of America, represented by the Secretary, Department of Health and Human Services, Astellas Pharma Inc.Inventors: Yoshinori Naoe, Susan E. Bates
-
Patent number: 8470783Abstract: A therapeutic agent for prostate cancer and malignant lymphoma containing FK228 or a salt thereof as an active ingredient, and a method for evaluating an antitumor effect of a histone deacetylase inhibitor which includes at least a step of treating a test cell with a histone deacetylase inhibitor, a step of measuring change in the expression amount of a specific gene in the test cell before and, after the treatment with the inhibitor, comparing the both expression amounts.Type: GrantFiled: August 20, 2002Date of Patent: June 25, 2013Assignee: Astellas Pharma Inc.Inventors: Yuka Sasakawa, Yoshinori Naoe
-
Publication number: 20110160295Abstract: An antitumor agent containing, in combination, at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent, and a histone deacetylase inhibitor. According to the present invention, an antitumor agent causing reduced side effects and having a superior antitumor activity can be provided.Type: ApplicationFiled: March 11, 2011Publication date: June 30, 2011Applicant: Astellas Pharma Inc.Inventors: Yoshinori Naoe, Takeshi Inoue, Yasuhiko Kano
-
Patent number: 7951780Abstract: An antitumor agent containing, in combination, at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent, and a histone deacetylase inhibitor. According to the present invention, an antitumor agent causing reduced side effects and having a superior antitumor activity can be provided.Type: GrantFiled: February 24, 2005Date of Patent: May 31, 2011Assignee: Astellas Pharma Inc.Inventors: Yoshinori Naoe, Takeshi Inoue, Yasuhiko Kano
-
Publication number: 20080233562Abstract: The present invention provides a method of obtaining a gene capable of becoming an index for predicting the efficacy of a histone deacetylase inhibitor, which comprises at least (I) a step of dividing tumor cells into a histone deacetylase inhibitor sensitive tumor cell and a histone deacetylase inhibitor resistant tumor cell, and (II) a step of examining the gene expression pattern of each of the sensitive tumor cell and the resistant tumor cell, and a step of selecting (i) a gene showing high expression in the sensitive tumor cell and low expression in the resistant tumor cell, or (ii) a gene showing low expression in the sensitive tumor cell and high expression in the resistant tumor cell, in order to provide a gene useful for predicting the efficacy, particularly an antitumor effect, of a histone deacetylase inhibitor, for a tumor desired to be treated.Type: ApplicationFiled: February 10, 2004Publication date: September 25, 2008Applicant: Astellas Pharma Inc.Inventors: Yuka Sasakawa, Yoshinori Naoe
-
Patent number: 7314862Abstract: The present invention relates to an antitumor agent containing a histone deacetylase inhibitor and a topoisomerase II inhibitor in combination. This combination has been found to exhibit a synergistic anticancer or antitumor effect compared to administration of either the histone deacetylase alone or the topoisomerase II inhibitor alone. Thus, this combination provides a tumor or cancer treatment with fewer side effects since a lower dosage of both ingedients may be administered.Type: GrantFiled: September 24, 2004Date of Patent: January 1, 2008Assignee: Astellas Pharma Inc.Inventors: Yoshinori Naoe, Yuka Sasakawa
-
Publication number: 20060135413Abstract: The present invention provides a therapeutic agent of kidney cancer, which comprises FK228 of the formula (I) or a salt thereof. FK228 or a salt thereof, which is an active ingredient in the present invention, shows a superior antitumor activity in vivo against kidney cancer.Type: ApplicationFiled: March 27, 2003Publication date: June 22, 2006Inventors: Yoshinori Naoe, Susan Bates
-
Publication number: 20050191713Abstract: A therapeutic agent for prostate cancer and malignant lymphoma containing FK228 or a salt thereof as an active ingredient, and a method for evaluating an antitumor effect of a histone deacetylase inhibitor which includes at least a step of treating a test cell with a histone deacetylase inhibitor, a step of measuring change in the expression amount of a specific gene in the test cell before and, after the treatment with the inhibitor, comparing the both expression amounts.Type: ApplicationFiled: August 20, 2002Publication date: September 1, 2005Applicant: Fujisawa Pharmaceutical Co.. Ltd.Inventors: Yuka Sasakawa, Yoshinori Naoe
-
Publication number: 20050187149Abstract: An antitumor agent containing, in combination, at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent, and a histone deacetylase inhibitor. According to the present invention, an antitumor agent causing reduced side effects and having a superior antitumor activity can be provided.Type: ApplicationFiled: February 24, 2005Publication date: August 25, 2005Inventors: Yoshinori Naoe, Takeshi Inoue, Yasuhiko Kano
-
Publication number: 20050187148Abstract: An antitumor agent containing, in combination, at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent, and a histone deacetylase inhibitor. According to the present invention, an antitumor agent causing reduced side effects and having a superior antitumor activity can be provided.Type: ApplicationFiled: April 29, 2004Publication date: August 25, 2005Inventors: Yoshinori Naoe, Takeshi Inoue, Yasuhiko Kano
-
Publication number: 20050070467Abstract: The present invention relates to an antitumor agent containing a histone deacetylase inhibitor and a topoisomerase II inhibitor in combination, and an enhancer of antitumor effect of topoisomerase II inhibitor, which contains a histone deacetylase inhibitor as an active ingredient. The present invention provides an antitumor agent having superior antitumor activity, which is associated with a fewer side effects.Type: ApplicationFiled: September 24, 2004Publication date: March 31, 2005Applicant: FUJISAWA PHARMACEUTICAL CO., LTD.Inventors: Yoshinori Naoe, Yuka Sasakawa